Ï㽶ÊÓƵ

Sarah V. Colonna
( out of 35 reviews )

Sarah V. Colonna, MD

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Hospital North

2K, Plastic and Reconstructive Surgery
Salt Lake City

Veterans Administration Medical Center

Salt Lake City
801-582-1565

  • Dr. Sarah Colonna, MD specializes in caring for women at high risk for breast cancer. She is board certified in internal medicine and medical oncology. Dr. Colonna sees women at risk for breast cancer because of a known genetic mutation, a strong family history of breast cancer or abnormal findings on a breast biopsy. She researches the use of breast MRI as a tool to better quantify breast cancer risk and is involved with longitudinal studies to better understand how the environment can impact on a woman’s risk of breast cancer. Dr. Colonna is also specifically interested in how medical professionals communicate cancer risks to their patients.

    Specialties

    Board Certification

    American Board of Internal Medicine
    American Board of Internal Medicine (Sub: Medical Oncology)

    Patient Rating

    4.8 /5
    ( out of 35 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    October 17, 2024
    HUNTSMAN CANCER CENTER

    Compassionate health care provider who listens!

    October 11, 2024
    HUNTSMAN CANCER CENTER

    Phenomenal physician - really knows her stuff and is extremely kind and caring as well.

    September 16, 2024
    HUNTSMAN CANCER CENTER

    Dr. Colonna is an incredible physician. She took a substantial amount of time to talk with me about my specific medical history & risks and answered every question that we had. She was calm but direct. I entirely trust her to handle my care moving forward. Her clinic demonstrates the highest level of teamwork, and makes me feel confident about the future direction of medicine.

    April 12, 2024
    HUNTSMAN CANCER CENTER

    Dr. Colonna and team were very thorough. I found her advice to be thoughtful and helpful.

    January 28, 2024
    HUNTSMAN CANCER CENTER

    Superb - great listener; highly sophisticated; excellent care plan

    December 22, 2023
    HUNTSMAN CANCER CENTER

    I really liked Dr. Colonna. She made eye contact, listened attentively, asked questions, and included me in decision-making.

    November 03, 2023
    HUNTSMAN CANCER CENTER

    She is very friendly and caring. She explained things clearly

    October 26, 2023
    HUNTSMAN CANCER CENTER

    Dr colonna is an amazing doctor. She is so smart, collaborative and patient. I highly, highly recommend her.

    October 16, 2023
    HUNTSMAN CANCER CENTER

    Dr Colonna was extremely thorough and comprehensive and answered every question I had in depth. She is so caring and personal while being extremely knowledgeable. She explained the research and my options very in depth.

    See More Patient Comments

  • Dr. Sarah Colonna, MD specializes in caring for women at high risk for breast cancer. She is board certified in internal medicine and medical oncology. Dr. Colonna sees women at risk for breast cancer because of a known genetic mutation, a strong family history of breast cancer or abnormal findings on a breast biopsy. She researches the use of breast MRI as a tool to better quantify breast cancer risk and is involved with longitudinal studies to better understand how the environment can impact on a woman’s risk of breast cancer. Dr. Colonna is also specifically interested in how medical professionals communicate cancer risks to their patients.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Oncology
    Board Certification
    American Board of Internal Medicine
    American Board of Internal Medicine (Sub: Medical Oncology)

    Education history

    Graduate Training Clinical Investigation - Ï㽶ÊÓƵ of Utah M.S.
    Fellowship Hematology/Oncology - Ï㽶ÊÓƵ of Utah, Huntsman Cancer Institute Fellow
    Fellowship Hematology/Oncology - Vanderbilt Ï㽶ÊÓƵ Fellow
    Residency Internal Medicine - Wake Forest Ï㽶ÊÓƵ Resident
    Professional Medical Medicine - East Tennessee State Ï㽶ÊÓƵ, Quillen College of Medicine M.D.
    Undergraduate Biology, minor in Religion - Lee Ï㽶ÊÓƵ B.S.

    Selected Publications

    Journal Article

    1. Kaphingst KA, Kohlmann WK, Lorenz Chambers R, Bather JR, Goodman MS, Bradshaw RL, Chavez-Yenter D, Colonna SV, Espinel WF, Everett JN, Flynn M, Gammon A, Harris A, Hess R, Kaiser-Jackson L, Lee S, Monahan R, Schiffman JD, Volkmar M, Wetter DW, Zhong L, Mann DM, Ginsburg O, Sigireddi M, Kawamoto K, Del Fiol G, Buys SS (2024). Uptake of Cancer Genetic Services for Chatbot vs Standard-of-Care Delivery Models: The BRIDGE Randomized Clinical Trial. JAMA Netw Open, 7(9), e2432143. ()
    2. McDonald JA, Liao Y, Knight JA, John EM, Kurian AW, Daly M, Buys SS, Huang Y, Frost CJ, Andrulis IL, Colonna SV, Friedlander ML, Hopper JL, Chung WK, Genkinger JM, MacInnis RJ, Terry MB, Kathleen Cuningham Foundation Consortium investigators (2024). Pregnancy-Related Factors and Breast Cancer Risk for Women Across a Range of Familial Risk. JAMA Netw Open, 7(8), e2427441. ()
    3. Hazra A, Goldstein KM, Waltz SE, Chiba A, Colonna SV, Kelley MJ, Moss HA, Zullig LL (2024). Summary and Roadmap of Breast Cancer Research in the Veterans Affairs. Mil Med. ()
    4. Morra A, Schreurs MAC, Andrulis IL, Anton-Culver H, Augustinsson A, Beckmann MW, Behrens S, Bojesen SE, Bolla MK, Brauch H, Broeks A, Buys SS, Camp NJ, Castelao JE, Cessna MH, Chang-Claude J, Chung WK, NBCS Collaborators, Colonna SV, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, Dennis J, Devilee P, Drk T, Dunning AM, Dwek M, Easton DF, Eccles DM, Eriksson M, Evans DG, Fasching PA, Fehm TN, Figueroa JD, Flyger H, Gabrielson M, Gago-Dominguez M, Garca-Closas M, Garca-Senz JA, Genkinger J, Grassmann F, Gndert M, Hahnen E, Haiman CA, Hamann U, Harrington PA, Hartikainen JM, Hoppe R, Hopper JL, Houlston RS, Howell A, ABCTB Investigators, kConFab Investigators, Jakubowska A, Janni W, Jernstrm H, John EM, Johnson N, Jones ME, Kristensen VN, Kurian AW, Lambrechts D, Le Marchand L, Lindblom A, Lubiski J, Lux MP, Mannermaa A, Mavroudis D, Mulligan AM, Muranen TA, Nevanlinna H, Nevelsteen I, Neven P, Newman WG, Obi N, Offit K, Olshan AF, Park-Simon TW, Patel AV, Peterlongo P, Phillips KA, Plaseska-Karanfilska D, Polley EC, Presneau N, Pylks K, Rack B, Radice P, Rashid MU, Rhenius V, Robson M, Romero A, Saloustros E, Sawyer EJ, Schmutzler RK, Schuetze S, Scott C, Shah M, Smichkoska S, Southey MC, Tapper WJ, Teras LR, Tollenaar RAEM, Tomczyk K, Tomlinson I, Troester MA, Vachon CM, van Veen EM, Wang Q, Wendt C, Wildiers H, Winqvist R, Ziogas A, Hall P, Pharoah PDP, Adank MA, Hollestelle A, Schmidt MK, Hooning MJ (2023). Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival. Cancer Med, 12(15), 16142-16162. ()
    5. Kast K, John EM, Hopper JL, Andrieu N, Nogus C, Mouret-Fourme E, Lasset C, Fricker JP, Berthet P, Mari V, Salle L, Schmidt MK, Ausems MGEM, Garcia EBG, van de Beek I, Wevers MR, Evans DG, Tischkowitz M, Lalloo F, Cook J, Izatt L, Tripathi V, Snape K, Musgrave H, Sharif S, Murray J, EMBRACE Collaborators, Colonna SV, Andrulis IL, Daly MB, Southey MC, de la Hoya M, Osorio A, Foretova L, Berkova D, Gerdes AM, Olah E, Jakubowska A, Singer CF, Tan Y, Augustinsson A, Rantala J, Simard J, Schmutzler RK, Milne RL, Phillips KA, Terry MB, Goldgar D, van Leeuwen FE, Mooij TM, Antoniou AC, Easton DF, Rookus MA, Engel C (2023). Associations of height, body mass index, and weight gain with breast cancer risk in carriers of a pathogenic variant in BRCA1 or BRCA2: the BRCA1 and BRCA2 Cohort Consortium. Breast Cancer Res, 25(1), 72. ()
    6. Mueller SH, Lai AG, Valkovskaya M, Michailidou K, Bolla MK, Wang Q, Dennis J, Lush M, Abu-Ful Z, Ahearn TU, Andrulis IL, Anton-Culver H, Antonenkova NN, Arndt V, Aronson KJ, Augustinsson A, Baert T, Freeman LEB, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Blomqvist C, Bogdanova NV, Bojesen SE, Bonanni B, Brenner H, Brucker SY, Buys SS, Castelao JE, Chan TL, Chang-Claude J, Chanock SJ, Choi JY, Chung WK, NBCS Collaborators, Colonna SV, CTS Consortium, Cornelissen S, Couch FJ, Czene K, Daly MB, Devilee P, Drk T, Dossus L, Dwek M, Eccles DM, Ekici AB, Eliassen AH, Engel C, Evans DG, Fasching PA, Fletcher O, Flyger H, Gago-Dominguez M, Gao YT, Garca-Closas M, Garca-Senz JA, Genkinger J, Gentry-Maharaj A, Grassmann F, Gunel P, Gndert M, Haeberle L, Hahnen E, Haiman CA, Hkansson N, Hall P, Harkness EF, Harrington PA, Hartikainen JM, Hartman M, Hein A, Ho WK, Hooning MJ, Hoppe R, Hopper JL, Houlston RS, Howell A, Hunter DJ, Huo D, ABCTB Investigators, Ito H, Iwasaki M, Jakubowska A, Janni W, John EM, Jones ME, Jung A, Kaaks R, Kang D, Khusnutdinova EK, Kim SW, Kitahara CM, Koutros S, Kraft P, Kristensen VN, Kubelka-Sabit K, Kurian AW, Kwong A, Lacey JV, Lambrechts D, Le Marchand L, Li J, Linet M, Lo WY, Long J, Lophatananon A, Mannermaa A, Manoochehri M, Margolin S, Matsuo K, Mavroudis D, Menon U, Muir K, Murphy RA, Nevanlinna H, Newman WG, Niederacher D, OBrien KM, Obi N, Offit K, Olopade OI, Olshan AF, Olsson H, Park SK, Patel AV, Patel A, Perou CM, Peto J, Pharoah PDP, Plaseska-Karanfilska D, Presneau N, Rack B, Radice P, Ramachandran D, Rashid MU, Rennert G, Romero A, Ruddy KJ, Ruebner M, Saloustros E, Sandler DP, Sawyer EJ, Schmidt MK, Schmutzler RK, Schneider MO, Scott C, Shah M, Sharma P, Shen CY, Shu XO, Simard J, Surowy H, Tamimi RM, Tapper WJ, Taylor JA, Teo SH, Teras LR, Toland AE, Tollenaar RAEM, Torres D, Torres-Meja G, Troester MA, Truong T, Vachon CM, Vijai J, Weinberg CR, Wendt C, Winqvist R, Wolk A, Wu AH, Yamaji T, Yang XR, Yu JC, Zheng W, Ziogas A, Ziv E, Dunning AM, Easton DF, Hemingway H, Hamann U, Kuchenbaecker KB (2023). Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry. Genome Med, 15(1), 7. ()
    7. Li S, Silvestri V, Leslie G, Rebbeck TR, Neuhausen SL, Hopper JL, Nielsen HR, Lee A, Yang X, McGuffog L, Parsons MT, Andrulis IL, Arnold N, Belotti M, Borg, Buecher B, Buys SS, Caputo SM, Chung WK, Colas C, Colonna SV, Cook J, Daly MB, de la Hoya M, de Pauw A, Delhomelle H, Eason J, Engel C, Evans DG, Faust U, Fehm TN, Fostira F, Fountzilas G, Frone M, Garcia-Barberan V, Garre P, Gauthier-Villars M, Gehrig A, Glendon G, Goldgar DE, Golmard L, Greene MH, Hahnen E, Hamann U, Hanson H, Hassan T, Hentschel J, Horvath J, Izatt L, Janavicius R, Jiao Y, John EM, Karlan BY, Kim SW, Konstantopoulou I, Kwong A, Laug A, Lee JW, Lesueur F, Mebirouk N, Meindl A, Mouret-Fourme E, Musgrave H, Ngeow Yuen Yie J, Niederacher D, Park SK, Pedersen IS, Ramser J, Ramus SJ, Rantala J, Rashid MU, Reichl F, Ritter J, Rump A, Santamaria M, Saule C, Schmidt G, Schmutzler RK, Senter L, Shariff S, Singer CF, Southey MC, Stoppa-Lyonnet D, Sutter C, Tan Y, Teo SH, Terry MB, Thomassen M, Tischkowitz M, Toland AE, Torres D, Vega A, Wagner SA, Wang-Gohrke S, Wappenschmidt B, Weber BHF, Yannoukakos D, Spurdle AB, Easton DF, Chenevix-Trench G, Ottini L, Antoniou AC (2022). Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants. J Clin Oncol, JCO2102112. ()
    8. Morra A, Escala-Garcia M, Beesley J, Keeman R, Canisius S, Ahearn TU, Andrulis IL, Anton-Culver H, Arndt V, Auer PL, Augustinsson A, Beane Freeman LE, Becher H, Beckmann MW, Behrens S, Bojesen SE, Bolla MK, Brenner H, Brning T, Buys SS, Caan B, Campa D, Canzian F, Castelao JE, Chang-Claude J, Chanock SJ, Cheng TD, Clarke CL, NBCS Collaborators, Colonna SV, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, Dennis J, Drk T, Dossus L, Dunning AM, Dwek M, Eccles DM, Ekici AB, Eliassen AH, Eriksson M, Evans DG, Fasching PA, Flyger H, Fritschi L, Gago-Dominguez M, Garca-Senz JA, Giles GG, Grip M, Gunel P, Gndert M, Hahnen E, Haiman CA, Hkansson N, Hall P, Hamann U, Hart SN, Hartikainen JM, Hartmann A, He W, Hooning MJ, Hoppe R, Hopper JL, Howell A, Hunter DJ, ABCTB Investigators, kConFab Investigators, Jager A, Jakubowska A, Janni W, John EM, Jung AY, Kaaks R, Keupers M, Kitahara CM, Koutros S, Kraft P, Kristensen VN, Kurian AW, Lacey JV, Lambrechts D, Le Marchand L, Lindblom A, Linet M, Luben RN, Lubiski J, Lush M, Mannermaa A, Manoochehri M, Margolin S, Martens JWM, Martinez ME, Mavroudis D, Michailidou K, Milne RL, Mulligan AM, Muranen TA, Nevanlinna H, Newman WG, Nielsen SF, Nordestgaard BG, Olshan AF, Olsson H, Orr N, Park-Simon TW, Patel AV, Peissel B, Peterlongo P, Plaseska-Karanfilska D, Prajzendanc K, Prentice R, Presneau N, Rack B, Rennert G, Rennert HS, Rhenius V, Romero A, Roylance R, Ruebner M, Saloustros E, Sawyer EJ, Schmutzler RK, Schneeweiss A, Scott C, Shah M, Smichkoska S, Southey MC, Stone J, Surowy H, Swerdlow AJ, Tamimi RM, Tapper WJ, Teras LR, Terry MB, Tollenaar RAEM, Tomlinson I, Troester MA, Truong T, Vachon CM, Wang Q, Hurson AN, Winqvist R, Wolk A, Ziogas A, Brauch H, Garca-Closas M, Pharoah PDP, Easton DF, Chenevix-Trench G, Schmidt MK (2021). Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. Breast Cancer Res, 23(1), 86. ()
    9. Kaphingst KA, Kohlmann W, Chambers RL, Goodman MS, Bradshaw R, Chan PA, Chavez-Yenter D, Colonna SV, Espinel WF, Everett JN, Gammon A, Goldberg ER, Gonzalez J, Hagerty KJ, Hess R, Kehoe K, Kessler C, Kimball KE, Loomis S, Martinez TR, Monahan R, Schiffman JD, Temares D, Tobik K, Wetter DW, Mann DM, Kawamoto K, Del Fiol G, Buys SS, Ginsburg O, BRIDGE research team (2021). Comparing models of delivery for cancer genetics services among patients receiving primary care who meet criteria for genetic evaluation in two healthcare systems: BRIDGE randomized controlled trial. BMC Health Serv Res, 21(1), 542. ()
    10. Baron K, Moser JC, Patel S, Grossmann KF, Colonna SV, Hyngstrom JR (2020). Comparative effectiveness of second-line ipilimumab vs. nivolumab in combination with ipilimumab in patients with advanced melanoma who received frontline anti-PD-1 antibodies. J Oncol Pharm Pract, 27(3), 555-559. ()
    11. Choi YH, Terry MB, Daly MB, MacInnis RJ, Hopper JL, Colonna S, Buys SS, Andrulis IL, John EM, Kurian AW, Briollais L (2022). Association of Risk-Reducing Salpingo-Oophorectomy With Breast Cancer Risk in Women With BRCA1 and BRCA2 Pathogenic Variants. JAMA Oncol, 7(4), 585-592. ()
    12. Watt GP, Sung J, Morris EA, Buys SS, Bradbury AR, Brooks JD, Conant EF, Weinstein SP, Kontos D, Woods M, Colonna SV, Liang X, Stein MA, Pike MC, Bernstein JL (2020). Association of breast cancer with MRI background parenchymal enhancement: the IMAGINE case-control study. Breast Cancer Res, 22(1), 138. ()
    13. Knight JA, Kehm RD, Schwartz L, Frost CJ, Chung WK, Colonna S, Keegan THM, Goldberg M, Houghton LC, Hanna D, Glendon G, Daly MB, Buys SS, Andrulis IL, John EM, Bradbury AR, Terry MB (2020). Pre-Pubertal Internalizing Symptoms and Timing of Puberty Onset in Girls. Am J Epidemiol. ()
    14. Sutherland N, Espinel W, Grotzke M, Colonna S (2020). Unanswered Questions: Hereditary breast and gynecological cancer risk assessment in transgender adolescents and young adults. J Genet Couns, 29(4), 625-633. ()
    15. Silvestri V, Leslie G, Barnes DR, CIMBA Group, Agnarsson BA, Aittomki K, Alducci E, Andrulis IL, Barkardottir RB, Barroso A, Barrowdale D, Benitez J, Bonanni B, Borg A, Buys SS, Calds T, Caligo MA, Capalbo C, Campbell I, Chung WK, Claes KBM, Colonna SV, Cortesi L, Couch FJ, de la Hoya M, Diez O, Ding YC, Domchek S, Easton DF, Ejlertsen B, Engel C, Evans DG, Feliubadal L, Foretova L, Fostira F, Gczi L, Gerdes AM, Glendon G, Godwin AK, Goldgar DE, Hahnen E, Hogervorst FBL, Hopper JL, Hulick PJ, Isaacs C, Izquierdo A, James PA, Janavicius R, Jensen UB, John EM, Joseph V, Konstantopoulou I, Kurian AW, Kwong A, Landucci E, Lesueur F, Loud JT, Machackova E, Mai PL, Majidzadeh-A K, Manoukian S, Montagna M, Moserle L, Mulligan AM, Nathanson KL, Nevanlinna H, Ngeow J, Nikitina-Zake L, Offit K, Olah E, Olopade OI, Osorio A, Papi L, Park SK, Pedersen IS, Perez-Segura P, Petersen AH, Pinto P, Porfirio B, Pujana MA, Radice P, Rantala J, Rashid MU, Rosenzweig B, Rossing M, Santamaria M, Schmutzler RK, Senter L, Simard J, Singer CF, Solano AR, Southey MC, Steele L, Steinsnyder Z, Stoppa-Lyonnet D, Tan YY, Teixeira MR, Teo SH, Terry MB, Thomassen M, Toland AE, Torres-Esquius S, Tung N, van Asperen CJ, Vega A, Viel A, Vierstraete J, Wappenschmidt B, Weitzel JN, Wieme G, Yoon SY, Zorn KK, McGuffog L, Parsons MT, Hamann U, Greene MH, Kirk JA, Neuhausen SL, Rebbeck TR, Tischkowitz M, Chenevix-Trench G, Antoniou AC, Friedman E, Ottini L (2020). Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). JAMA Oncol, 6(8), 1218-1230. ()
    16. Moser JC, Wei G, Colonna SV, Grossmann KF, Patel S, Hyngstrom JR (2020). Comparative-effectiveness of pembrolizumab vs. nivolumab for patients with metastatic melanoma. Acta Oncol, 59(4), 434-437. ()
    17. Greenberg S, Slager S, Neil BO, Cooney K, Maughan B, Stopa N, Venne V, Zickmund S, Colonna S (2020). What men want: Qualitative analysis of what men with prostate cancer (PCa) want to learn regarding genetic referral, counseling, and testing. Prostate, 80(5), 441-450. ()
    18. Moser JC, Chen D, Hu-Lieskovan S, Grossmann KF, Patel S, Colonna SV, Ying J, Hyngstrom JR (2019). Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF/MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumab. Cancer Med, 8(18), 7637-7643. ()
    19. Colonna S, Sweetenham J, Burgon TB, Buys SS, Lynch R, Au T, Johnson E, Kubal T, Paculdo D, Acelajado MC, Peabody JW (2018). A Better Pathway? Building Consensus and Engaging Providers with Feedback to Improve and Standardize Cancer Care. Clin Breast Cancer, 19(2), e376-e384. ()
    20. Colonna S, Curtin K, Johnson E, Kohlmann W, Wright J, Kirchhoff A, Tavtigian S, Schiffman J (2019). Family History of Breast Cancer Associated with Breast Cancer in Survivors of Hodgkin Lymphoma. Int J Cancer Clin Res, 6(1). ()
    21. Carmichael H, Matsen C, Freer P, Kohlmann W, Stein M, Buys SS, Colonna S (2017). Breast cancer screening of pregnant and breastfeeding women with BRCA mutations. Breast Cancer Res Treat, 162(2), 225-230. ()
    22. Carmicheal H, Matsen C, Freer P, Kohlmann W, Stein M, Buys SS, Colonna S, MD (2017). Breast cancer screening of pregnant and breastfeeding women with BRCA mutations. doi: 10.1007/s10549-017-4122-y. Review. PubMed PMID: 28138892. Breast Cancer Res Treat, 162(2), 225-230.
    23. Colonna SV, Higgins AK, Alvarez J, Saville BR, Lawrence J, Abramson VG (2015). Analysis of Risk of Recurrence by Subtype in ≤ 1-cm Breast Tumors. Clin Breast Cancer, 16(3), 223-31. ()
    24. Colonna S, Halwani A, Ying J, Buys S, Sweeney C (2015). Women with breast cancer in the Veterans Health Administration: demographics, breast cancer characteristics, and trends. Med Care, 53(4 Suppl 1), S149-55. ()
    25. Colonna SV, Douglas Case L, Lawrence JA (2011). A retrospective review of the metabolic syndrome in women diagnosed with breast cancer and correlation with estrogen receptor. Breast Cancer Res Treat, 131(1), 325-31. ()

    Book Chapter

    1. Colonna SV, Gammon A (2016). Management of the Patient with a Genetic Predisposition for Breast Cancer. In Dr. Ismail Jatoi and Dr. Achim Rody (Eds.), Management of Breast Diseases (Second Edition).
    2. Colonna SV, Werner T (2015). Breast cancer bone metastases. In Lor Randall (Ed.), Metastatic Bone Disease: Essentials for the Orthopedic Surgeon. Springer International.
    3. Colonna SV, Goff L, Berlin J (2013). Biliary Tree Cancer. In Decision Support in Medicine: Oncology.

    Editorial

    1. Kohlmann W, Champine M, Colonna SV (May 31, 2015). Communicating Genetic Test Results to Patients and Their Families. ASCO Daily News.

    Abstract

    1. Colonna SV, Curtin K, Kohlmann W, Wright J, Tavtigian S, Schiffman J (2015). Family history of breast cancer in Hodgkin disease and future risk of breast cancer. [Abstract]. J Clin Oncol, 33(suppl), abstr 1522.
    2. Halwani A, Colonna SV, Ying J, Buys S, Sweeney C (2014). Geographic distribution of rural-urban status of women with breast cancer in the Veterans Health Administration using two schemes: Rural Urban Continuum and Rural Urban Commuting Areas [Abstract]. Association of VA Hematology/Oncology.
    3. Colonna SV, Halwani A, Ying J, Sweeney C, Buys S (2014). Breast cancer treatment among rural and urban veterans at the Veterans Health Administration: also presented as a poster. [Abstract]. Association of VA Hematology/Oncology.
    4. Udomaksorn S, Stenehjem D, Welch BM, Cheng Y, Anderson L, Colonna S, Neumayer L, Brixner D (2013). Evaluation of variable relevance and accessibility to support personalized medicine in breast cancer [Abstract]. ISPOR 16th Annual European Congress, Dublin, Ireland.
    5. Colonna SV, Higgins AK, Alvarez J, Saville B, Lawrence JA, Abramson VA (2013). Analysis of recurrence risk by subtype in <1cm breast tumors [Abstract]. Journal of Clinical Oncology.
    6. Colonna SV, Douglas Case L, Lawrence JA (2009). Correlation of the Metabolic Syndrome with Estrogen Receptor Negative Breast Cancer in a Retrospective Review [Abstract].

  • Clinical Trials